Does gene therapy become pharmacotherapy?
Recent progress in molecular and cellular biology has led to the development of numerous effective cardiovascular drugs. However, there are still a number of diseases for which no known effective therapy exists, such as peripheral arterial disease, ischaemic heart disease, restenosis after angioplasty, and vascular bypass graft occlusion. Currently, gene therapy is emerging as a potential strategy for the treatment of cardiovascular disease despite its limitations. The first human trial in gene therapy for cardiovascular disease was started at 1994 to treat peripheral vascular disease using vascular endothelial growth factor (VEGF). Then, many different potent angiogenic growth factors were tested in clinical trials to treat peripheral arterial disease and ischaemic heart disease. Improvement of clinical symptoms in peripheral arterial disease and ischaemic heart disease has been reported. This review focuses on the future potential of gene therapy for the treatment of cardiovascular disease. In the future, gene therapy might become a real pharmacotherapy to treat cardiovascular disease.
Morishita
Ryuichi
R
Division of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita 565-0871, Japan. morishit@cgt.med.osaka-u.ac.jp
Aoki
Motokuni
M
Ogihara
Toshio
T
D000818:Animals; D002318:Cardiovascular Diseases / Q000235:genetics* / Q000628:therapy*; D002986:Clinical Trials as Topic; D004358:Drug Therapy / Q000379:methods* / Q000639:trends*; D018390:Gene Targeting / Q000379:methods* / Q000639:trends*; D018014:Gene Transfer Techniques / Q000639:trends; D015316:Genetic Therapy / Q000379:methods* / Q000639:trends*; D006801:Humans